Table 5.

Sensitivity of 6 antigens (in combinations of 1, 2 or 3 antigen panels) to predict recurrence prior to clinical recurrence in 21 ovarian cancer patients

Antigen (Single or in combination of 2 or 3 antigen panels)	Sensitivity of antigen panels to predict recurrence in 21 ovarian cancer patients
Ro52	52.4% (11/21)
CDR2	71.4% (15/21)
HARS	66.7% (14/21)
4B7	14.3% (3/21)
4H4	14.3% (3/21)
5H6	14.3% (3/21)
Ro52+CDR2	86% (18/21)
CDR2+HARS	81% (17/21)
Ro52+HARS	81% (17/21)
Ro52+5H6	62% (13/21)
CDR2+4B7 or CDR2+4H4 or CDR2+5H6	76% (16/21)
HARS+5H6	71.4% (15/21)
Ro52+CDR2+5H6 *	90.5% (19/21)
HARS+CDR2+5H6 or Ro52+CDR2+HARS	86% (18/21)
CDR2+4B7+5H6 or CDR2+4H4+5H6	80.9% (17/21)
Ro52+4B7+5H6 or Ro52+4H4+5H6	61.9% (13/21)

Note:

^*Combination of 3 antigens that resulted in highest sensitivity